In the United States,<unk>  is indicated for patients 12 years and older for the prophylaxis of hereditary angioedema (HAE) attacks. There is no data on the efficacy or safety of<unk>  in patients under the age of 12 years old.<unk>  was not studied in pregnant or breastfeeding women.
Lanadelumab
Ustekinumab
Olaratumab
Alirocumab
Evolocumab
Tralokinumab
Evinacumab
Emapalumab